In:
Cancer, Wiley, Vol. 129, No. 20 ( 2023-10-15), p. 3252-3262
Kurzfassung:
Annual spending attributable to metastatic prostate cancer was $55,949 per person‐year in the population covered by commercial insurance and $43,682 in the population covered by employer‐sponsored Medicare supplement plans, both in 2019 US dollars. These estimates can improve the precision of value assessments of clinical and policy approaches to the prevention, screening, and treatment of prostate cancer in the United States.
Materialart:
Online-Ressource
ISSN:
0008-543X
,
1097-0142
DOI:
10.1002/cncr.v129.20
Sprache:
Englisch
Verlag:
Wiley
Publikationsdatum:
2023
ZDB Id:
1479932-7
ZDB Id:
2599218-1
ZDB Id:
2594979-2
ZDB Id:
1429-1